Mumps - Clinical trials 

Clinical trials for Mumps

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Mumps. For all clinical trials, go to clinical trials search

This list shows clinical trials for Mumps

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Mumps
Title Recruitment status Location
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Not recruiting United Kingdom
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD’s dTpa-IPV vaccine (Repevax), when co-administered with GSK Biologicals’ MMR vaccine (Priorix) in 3 and 4-year-old healthy children. - DTPA-IPV (BOOSTRIX-IPV)-009 Authorised United Kingdom
The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants Recruiting Israel
A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children Recruiting China
Immunogenicity and safety assessments of MMR vaccine with new mumpes component (RS12) Recruiting Iran, Islamic Republic Of
Topical coating of measles-mumps-rubella vaccine for the treatment of respiratory papilloma Recruiting China
Ontogeny of Measles Immunity in Infants Recruiting United States
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Recruiting Korea, Republic of
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Recruiting Puerto Rico
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Recruiting Taiwan